| 21.87 -0.6 (-2.67%) | 04-27 13:23 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.68  |
1-year : | 32.96 |
| Resists | First : | 25.41 |
Second : | 28.22 |
| Pivot price | 0 | |||
| Supports | First : | 20.86 |
Second : | 17.35 |
| MAs | MA(5) : | 23.71 |
MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 28.22 | Low : | 20.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KLRA ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 25.33 - 25.45 | 25.45 - 25.55 |
| Low: | 21.79 - 21.94 | 21.94 - 22.07 |
| Close: | 22.26 - 22.49 | 22.49 - 22.68 |
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.
Mon, 27 Apr 2026
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million - The Motley Fool
Mon, 27 Apr 2026
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million - Yahoo Finance
Sun, 26 Apr 2026
GLP-1 developer Kailera, proteomics firm Alamar file for US IPOs - MSN
Sat, 25 Apr 2026
KLRA (Kailera Therapeutics) PB Ratio : (As of Apr. 25, 2026) - GuruFocus
Fri, 24 Apr 2026
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Sahm
Thu, 23 Apr 2026
Bain Capital Life Sciences Secures Board Role at Kailera Therapeutics with 17.4% Stake - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|